Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: A population-based cohort study

Wen Hsuan Hou, Kai Cheng Chang, Chung Yi Li, Huang Tz Ou

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This is the first large longitudinal cohort study to investigate the putative association of severe joint pain (SJP) with dipeptidyl peptidase-4 inhibitor (DPP4i) use in patients with type 2 diabetes. The propensity score-matched population-based cohort study was performed between 2009 and 2013 in a group of type 2 diabetes patients with stable metformin use. In total, 4743 patients with type 2 diabetes used a DPP4i as the second-line antidiabetic drug (ie, DPP4i users), and the same number of matched non-DPP4i users was selected. The 2 study groups were followed up until SJP diagnosis (International Classification of Diseases, Ninth Reversion, Clinical Modification code 719.4), health insurance policy termination, or the end of 2013. The incidence rate of SJP was estimated under the Poisson assumption. Multiple Cox proportional hazard model was used to estimate the covariate-adjusted hazard ratio and 95% CI of SJP in association with DPP4i use. Over a maximum follow-up of 5 years, 679 DPP4i users and 767 non-DPP4i users were newly diagnosed with SJP, representing incidence rates of 47.20 and 50.66 per 1000 person-years, respectively. Cox proportional hazard model indicated that DPP4i use slightly but nonsignificantly reduced the risk of SJP (adjusted hazard ratio: 0.92 [95% CI: 0.83-1.02]). Such null results were also observed among all age and sex stratifications and in a sensitivity analysis using all nonspecific arthropathies as the study endpoint. This study provides no support for the putative risk of SJP related to DPP4i use in type 2 diabetes patients during a maximum follow-up of 5 years.

Original languageEnglish
Pages (from-to)1954-1959
Number of pages6
JournalPain
Volume157
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Arthralgia
Type 2 Diabetes Mellitus
Cohort Studies
Population
Protease Inhibitors
Proportional Hazards Models
Propensity Score
Joint Diseases
Metformin
Incidence
International Classification of Diseases
Health Insurance
Health Policy
Hypoglycemic Agents
Longitudinal Studies

Keywords

  • Cohort
  • Dipeptidyl peptidase-4 inhibitor
  • Severe joint pain
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes : A population-based cohort study. / Hou, Wen Hsuan; Chang, Kai Cheng; Li, Chung Yi; Ou, Huang Tz.

In: Pain, Vol. 157, No. 9, 01.09.2016, p. 1954-1959.

Research output: Contribution to journalArticle

@article{9da13b4597174505947a0c258ad6554d,
title = "Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: A population-based cohort study",
abstract = "This is the first large longitudinal cohort study to investigate the putative association of severe joint pain (SJP) with dipeptidyl peptidase-4 inhibitor (DPP4i) use in patients with type 2 diabetes. The propensity score-matched population-based cohort study was performed between 2009 and 2013 in a group of type 2 diabetes patients with stable metformin use. In total, 4743 patients with type 2 diabetes used a DPP4i as the second-line antidiabetic drug (ie, DPP4i users), and the same number of matched non-DPP4i users was selected. The 2 study groups were followed up until SJP diagnosis (International Classification of Diseases, Ninth Reversion, Clinical Modification code 719.4), health insurance policy termination, or the end of 2013. The incidence rate of SJP was estimated under the Poisson assumption. Multiple Cox proportional hazard model was used to estimate the covariate-adjusted hazard ratio and 95{\%} CI of SJP in association with DPP4i use. Over a maximum follow-up of 5 years, 679 DPP4i users and 767 non-DPP4i users were newly diagnosed with SJP, representing incidence rates of 47.20 and 50.66 per 1000 person-years, respectively. Cox proportional hazard model indicated that DPP4i use slightly but nonsignificantly reduced the risk of SJP (adjusted hazard ratio: 0.92 [95{\%} CI: 0.83-1.02]). Such null results were also observed among all age and sex stratifications and in a sensitivity analysis using all nonspecific arthropathies as the study endpoint. This study provides no support for the putative risk of SJP related to DPP4i use in type 2 diabetes patients during a maximum follow-up of 5 years.",
keywords = "Cohort, Dipeptidyl peptidase-4 inhibitor, Severe joint pain, Type 2 diabetes",
author = "Hou, {Wen Hsuan} and Chang, {Kai Cheng} and Li, {Chung Yi} and Ou, {Huang Tz}",
year = "2016",
month = "9",
day = "1",
doi = "10.1097/j.pain.0000000000000596",
language = "English",
volume = "157",
pages = "1954--1959",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes

T2 - A population-based cohort study

AU - Hou, Wen Hsuan

AU - Chang, Kai Cheng

AU - Li, Chung Yi

AU - Ou, Huang Tz

PY - 2016/9/1

Y1 - 2016/9/1

N2 - This is the first large longitudinal cohort study to investigate the putative association of severe joint pain (SJP) with dipeptidyl peptidase-4 inhibitor (DPP4i) use in patients with type 2 diabetes. The propensity score-matched population-based cohort study was performed between 2009 and 2013 in a group of type 2 diabetes patients with stable metformin use. In total, 4743 patients with type 2 diabetes used a DPP4i as the second-line antidiabetic drug (ie, DPP4i users), and the same number of matched non-DPP4i users was selected. The 2 study groups were followed up until SJP diagnosis (International Classification of Diseases, Ninth Reversion, Clinical Modification code 719.4), health insurance policy termination, or the end of 2013. The incidence rate of SJP was estimated under the Poisson assumption. Multiple Cox proportional hazard model was used to estimate the covariate-adjusted hazard ratio and 95% CI of SJP in association with DPP4i use. Over a maximum follow-up of 5 years, 679 DPP4i users and 767 non-DPP4i users were newly diagnosed with SJP, representing incidence rates of 47.20 and 50.66 per 1000 person-years, respectively. Cox proportional hazard model indicated that DPP4i use slightly but nonsignificantly reduced the risk of SJP (adjusted hazard ratio: 0.92 [95% CI: 0.83-1.02]). Such null results were also observed among all age and sex stratifications and in a sensitivity analysis using all nonspecific arthropathies as the study endpoint. This study provides no support for the putative risk of SJP related to DPP4i use in type 2 diabetes patients during a maximum follow-up of 5 years.

AB - This is the first large longitudinal cohort study to investigate the putative association of severe joint pain (SJP) with dipeptidyl peptidase-4 inhibitor (DPP4i) use in patients with type 2 diabetes. The propensity score-matched population-based cohort study was performed between 2009 and 2013 in a group of type 2 diabetes patients with stable metformin use. In total, 4743 patients with type 2 diabetes used a DPP4i as the second-line antidiabetic drug (ie, DPP4i users), and the same number of matched non-DPP4i users was selected. The 2 study groups were followed up until SJP diagnosis (International Classification of Diseases, Ninth Reversion, Clinical Modification code 719.4), health insurance policy termination, or the end of 2013. The incidence rate of SJP was estimated under the Poisson assumption. Multiple Cox proportional hazard model was used to estimate the covariate-adjusted hazard ratio and 95% CI of SJP in association with DPP4i use. Over a maximum follow-up of 5 years, 679 DPP4i users and 767 non-DPP4i users were newly diagnosed with SJP, representing incidence rates of 47.20 and 50.66 per 1000 person-years, respectively. Cox proportional hazard model indicated that DPP4i use slightly but nonsignificantly reduced the risk of SJP (adjusted hazard ratio: 0.92 [95% CI: 0.83-1.02]). Such null results were also observed among all age and sex stratifications and in a sensitivity analysis using all nonspecific arthropathies as the study endpoint. This study provides no support for the putative risk of SJP related to DPP4i use in type 2 diabetes patients during a maximum follow-up of 5 years.

KW - Cohort

KW - Dipeptidyl peptidase-4 inhibitor

KW - Severe joint pain

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84984636483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984636483&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000000596

DO - 10.1097/j.pain.0000000000000596

M3 - Article

AN - SCOPUS:84984636483

VL - 157

SP - 1954

EP - 1959

JO - Pain

JF - Pain

SN - 0304-3959

IS - 9

ER -